Catalyst Pharma director’s awards cashed out in merger
CATALYST PHARMACEUTICALS director Daniel J. Curran reported dispositions of equity awards to the issuer in connection with the consummation of a Merger.
Rhea-AI Filing Summary
CATALYST PHARMACEUTICALS director Daniel J. Curran reported dispositions of equity awards to the issuer in connection with the consummation of a Merger. On 2026-07-15, 5,468 restricted stock units and stock options over 18,115 and 40,000 shares of common stock were cancelled. Each restricted stock unit represented a contingent right to receive one share, and each award was converted into a right to receive a cash payment based on a $31.50 per-share merger price, less the applicable option exercise prices. All reported options and RSUs vested in full at closing, and these derivative positions now show zero shares following the transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Disposition: 63,583 shares
Disposition
3 txns
Insider
Curran Daniel J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F2, F4 | 40,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F2, F4 | 18,115 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F1, F3, F4 | 5,468 | $0.00 | $0.00 |
Holdings After Transaction:
Options to purchase common stock — 0 contracts (Direct);
Restricted Stock Units — 0 contracts (Direct)
Footnotes (4)
- F1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F3. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F4. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
RSUs canceled: 5,468 shares
Options canceled (grant 1): 18,115 shares at $22.77
Options canceled (grant 2): 40,000 shares at $21.12
+3 more
6 metrics
RSUs canceled
5,468 shares
Restricted stock units converted to cash rights at $31.50 per share
Options canceled (grant 1)
18,115 shares at $22.77
Options to purchase common stock canceled and cashed out in Merger
Options canceled (grant 2)
40,000 shares at $21.12
Options to purchase common stock canceled and cashed out in Merger
Merger reference price
$31.50 per share
Per-share amount used to calculate cash for RSUs and options
RSU expiration date
2028-11-20
Original expiration date of reported RSUs before Merger cancellation
Option expiration dates
2032-11-20 and 2032-08-01
Original expirations for canceled option grants
Key Terms
restricted stock unit, Merger, Options to purchase common stock, per-share price, +1 more
5 terms
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Merger financial
"In connection with the consummation of the Merger, each reported stock option"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
Options to purchase common stock financial
"Options to purchase common stock were cancelled and converted into cash rights"
cash payment (without interest, and less applicable tax withholdings) financial
"was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings"
FAQ
What insider transactions did Daniel J. Curran report for CPRX?
Daniel J. Curran reported dispositions of equity awards to Catalyst Pharmaceuticals in connection with a Merger. He had 5,468 RSUs and stock options over 18,115 and 40,000 shares canceled and converted into cash-based rights tied to a $31.50 per-share merger price.
Were Daniel J. Curran’s CPRX equity awards sold on the open market?
No. The filing shows the RSUs and options were disposed to the issuer and canceled in connection with a Merger. They were converted into rights to receive cash payments based on a $31.50 per-share merger price, not sold through market trades.
How many Catalyst Pharmaceuticals RSUs and options were affected for CPRX director Daniel J. Curran?
The report lists 5,468 restricted stock units and options over 18,115 and 40,000 shares of common stock. Each RSU equaled one share, and all these awards were canceled and cashed out using a $31.50 per-share merger reference price.
What cash value reference price was used for Daniel J. Curran’s CPRX awards in the Merger?
The awards were valued using a $31.50 per-share merger price. RSUs were converted into cash equal to $31.50 times the RSU share count, while options received cash equal to $31.50 minus the per-share exercise price, multiplied by shares covered.
Did Daniel J. Curran’s CPRX options and RSUs vest before being canceled?
Yes. A footnote states that each Option or RSU vested in full in connection with the Merger’s consummation. After vesting, the awards were canceled and converted into rights to receive cash payments based on the $31.50 merger price mechanics.
Were Daniel J. Curran’s CPRX Form 4 transactions under a Rule 10b5-1 plan?
No. The Form 4’s Rule 10b5-1 checkbox is not marked, so these dispositions were not reported as executed under a Rule 10b5-1 trading plan. Instead, they occurred automatically in connection with the Merger and related award cancellation terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
